-
公开(公告)号:US20060009658A1
公开(公告)日:2006-01-12
申请号:US10885277
申请日:2004-07-06
申请人: Chih Ho , Eric Strobel
发明人: Chih Ho , Eric Strobel
IPC分类号: C07C259/04
CPC分类号: C07C259/06 , C07C259/10 , C07C303/40 , C07C311/29 , C07D209/42 , C07D217/26
摘要: The present invention provides a novel method for the formation of hydroxamic acids comprising reacting under suitable conditions an ester with hydroxylamine in the presence of cyanide anion.
-
公开(公告)号:US20050197354A1
公开(公告)日:2005-09-08
申请号:US11111358
申请日:2005-04-21
申请人: Koenraad Jozef Andries , Bart De Corte , Marc De Jonge , Jan Heeres , Chih Ho , Marcel Janssen , Paul Janssen , Lucien Koymans , Michael Kukla , Donald Ludovici , Koen Van Aken
发明人: Koenraad Jozef Andries , Bart De Corte , Marc De Jonge , Jan Heeres , Chih Ho , Marcel Janssen , Paul Janssen , Lucien Koymans , Michael Kukla , Donald Ludovici , Koen Van Aken
IPC分类号: C07D239/42 , C07D239/46 , C07D239/48 , C07D239/50 , C07D401/12 , A61K31/506 , C07D43/02
CPC分类号: C07D239/42 , C07D239/47 , C07D239/48 , C07D239/49 , C07D239/50 , C07D401/12
摘要: This invention concerns the use of the compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein A is CH, CR4 or N; n is 0 to 4; Q is hydrogen or —NR1R2; R1 and R2 are selected from hydrogen, hydroxy, C1-12alkyl, C1-12alkyloxy, C1-12alkylcarbonyl, C1-12alkyloxycarbonyl, aryl, amino, mono- or di(C1-12alkyl)-amino, mono- or di(C1-12alkyl)aminocarbonyl wherein each C1-12alkyl may optionally be substituted; or R1 and R2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C1-12alkyl)aminoC1-4alkylidene; R3 is hydrogen, aryl. C1-6alkylcarbonyl, optionally substituted C1-6alkyl, C1-6alkyloxy-carbonyl; and R4 is hydroxy, halo, optionally substituted C1-6alkyl, C1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy; R5 is hydrogen or C1-4alkyl; L is optionally substituted C1-10alkyl, C3-10alkenyl, C3-10alkynyl, C3-7cycloalkyl; or L is —X1—R6 or —X2-Alk-R7 wherein R6 and R7 are optionally substituted phenyl; X1 and X2 are —NR3—, —NH—NH—, —N═N—, —O—, —S—, —S(═O)— or —S(═O)2—; Alk is C1-4alkanediyl; aryl is potionally substituted phenyl; Het is an optionally substituted aliphatic or aromatic heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection. It further relates to new compounds being a subgroup of the compounds of formula (I), their preparation and compositions comprising them.
-